Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
Recent News & Events
Imminent Q3 earnings (Nov 4) with Street forecasts lagging raised guidance is the dominant near-term catalyst; setup is asymmetric with limited room for a stumble after a 71% rally.
NEUTRALNov 4, 2026
Earnings Report
Q3 2026 results due November 4, 2026
Caris will report Q3 2026 financial results on November 4, 2026, with a webcast at 4:30 p.m. ET. Consensus revenue of ~$250.9M sits ~$13M below Q2's $263.7M and full-year consensus (~$989M) is below the low end of management's raised $1.03B-$1.04B guidance, creating potential for a beat-and-raise or a sharp negative reaction if volumes stall. Key watch items include clinical volume/pricing trends, Caris Detect ramp, gross margin near 68%, and free cash flow breakeven.
BofA Securities lifted its price target to $35, well above the $26.50 consensus and $27.08 average target, following a ~10% pullback on October 6. The constructive valuation signals the firm views the selloff as disconnected from the growth trajectory, providing a supportive backdrop into earnings, though the event is somewhat dated and its incremental impact may be fading.
National Caris Detect ad campaign featuring Jordan Spieth
Caris launched the second commercial in its Caris Detect MCED series featuring Jordan Spieth, timed with the direct-to-consumer ad campaign management flagged as due around now. Early read on order trends, backlog, or capacity strain from Detect—excluded from guidance—could be a swing factor in the Q3 report and near-term sentiment.
Board member discloses 400,000-share sale at $30.33
A board member disclosed a sale of 400,000 shares at $30.33 in a recent filing, part of heavy insider selling activity around the October 6 pullback. While insider sales are common, the size and timing near highs could weigh modestly on sentiment and warrant monitoring for further disclosures.
Caris unveiled an enhanced Caris Assure integrating WES, WTS, and whole-blood analysis with ~7-day turnaround, expanding clinical utility and supporting the blood-based Assure growth narrative (Q2 Assure cases +50%). Progress on New York approval for Assure is a potential near-term catalyst referenced ahead of earnings.